JP2024129140A5 - - Google Patents

Download PDF

Info

Publication number
JP2024129140A5
JP2024129140A5 JP2024108997A JP2024108997A JP2024129140A5 JP 2024129140 A5 JP2024129140 A5 JP 2024129140A5 JP 2024108997 A JP2024108997 A JP 2024108997A JP 2024108997 A JP2024108997 A JP 2024108997A JP 2024129140 A5 JP2024129140 A5 JP 2024129140A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
fev
asthma
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024108997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024129140A (ja
Filing date
Publication date
Priority claimed from JP2020067766A external-priority patent/JP2020125304A/ja
Application filed filed Critical
Publication of JP2024129140A publication Critical patent/JP2024129140A/ja
Publication of JP2024129140A5 publication Critical patent/JP2024129140A5/ja
Pending legal-status Critical Current

Links

JP2024108997A 2013-08-12 2024-07-05 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法 Pending JP2024129140A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12
JP2020067766A JP2020125304A (ja) 2013-08-12 2020-04-03 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法
JP2022092222A JP2022120010A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022092222A Division JP2022120010A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法

Publications (2)

Publication Number Publication Date
JP2024129140A JP2024129140A (ja) 2024-09-26
JP2024129140A5 true JP2024129140A5 (https=) 2025-08-05

Family

ID=52448838

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016534615A Active JP6746496B2 (ja) 2013-08-12 2014-08-07 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法
JP2020067766A Withdrawn JP2020125304A (ja) 2013-08-12 2020-04-03 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法
JP2022092222A Pending JP2022120010A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法
JP2024108997A Pending JP2024129140A (ja) 2013-08-12 2024-07-05 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016534615A Active JP6746496B2 (ja) 2013-08-12 2014-08-07 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法
JP2020067766A Withdrawn JP2020125304A (ja) 2013-08-12 2020-04-03 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法
JP2022092222A Pending JP2022120010A (ja) 2013-08-12 2022-06-07 ベンラリツマブを使用して喘息患者の努力肺活量を増大させる方法

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3033104B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN105451769A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2866426T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE043497T2 (https=)
LT (2) LT3520811T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3520811T3 (https=)
PT (2) PT3520811T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT201900311T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Similar Documents

Publication Publication Date Title
JP2024129140A5 (https=)
JP2025038127A5 (https=)
Tamm et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice
JP2023052457A5 (https=)
Rasheed et al. A review of natural steroids and their applications
CZ219196A3 (en) Application of mometasonfuorate aqueous suspension for preparing a medicament for effective intranasal treatment of nasal allergy
JP2006502969A (ja) 内因性性腺刺激ホルモン産生の増強
JP2013523683A5 (https=)
US8877740B2 (en) Compound composition for inhalation used for treating asthma
JPWO2019241442A5 (https=)
Mehdipour et al. Role of corticosteroids in oral lesions
US11571412B2 (en) Thromboxane receptor antagonists in AERD/asthma
EA009935B1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
JPWO2020223541A5 (https=)
CN120284871B (zh) 用于鼻腔的含奥洛他定与溴莫尼定的复方制剂组合物及其制备方法
WO2021260591A1 (en) Methods of reducing mortality in patients suffering from copd
WO2003022292A1 (fr) Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation
JP2022532220A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
EA009990B1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
JP2005518437A (ja) 自己免疫疾患の治療のための生体エストリオール・スルファミン酸エステル・プロドラックの使用
WO2025119815A1 (en) Combination preparation for the treatment of acute and chronic rhinosinusitis and/or allergic rhinitis
JPWO2021067297A5 (https=)
JPWO2021048280A5 (https=)
WO2022264097A1 (en) Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
WO2026052081A1 (zh) 用于治疗乙型肝炎的药物及组合